I can extract side effects

As a global pharmaceutical giant, every move of Sanqing affects the hearts of its competitors.

With the continuous disclosure of the clinical data of oral insulin on the official website, other insulin manufacturers are terrified and ashamed.

It's not that they haven't made efforts to take insulin orally, but the effect is dismal, and they still can't overcome the difficulty of absorption in the digestive tract, and soon die down.

Novo Nordisk once made a high-profile entry into the research and development of oral insulin, claiming to invest 3.6 billion U.S. dollars, and planned to launch the product within ten years. As a result, it stopped the business three years later.

Because the oral insulin they developed is difficult to pass through the intestinal barrier, and its bioavailability is extremely low, which means that a drug requires more insulin than an injection, and more than half of it is wasted on the road, which in vain increases the pressure on production capacity.

Pfizer once developed and marketed the first inhaled insulin, but because of the poor flexibility of administration and low acceptance, it was withdrawn from the market in the second year, and the investment of 2.7 billion U.S. dollars was completely in vain.

Sanofi also invested 2 billion U.S. dollars and spent 7 years developing another inhaled insulin. As a result, because of the low peak biological activity, long-term medication and the risk of affecting lung function, the market did not recognize it at all, and it sold less than a year. $5 million and had to be delisted after two years.

Therefore, on the track of oral insulin, there are piles of bones of major pharmaceutical giants, which has sounded the alarm for future generations.

Over time, many companies dare not try again.

Unexpectedly, Sanqing was able to make a breakthrough, successfully developed oral insulin, and successfully entered the clinical stage.

Insulin injections are no good at all.

After reading the reports from overseas media, Wei Kang followed suit and published a paper on oral insulin in the latest issue of "Life", which immediately attracted the attention of scientific research institutions around the world.

Since the publication of the "Life" journal, it has always been published in Chinese. Overseas scholars were quite critical at first, but later they gradually acquiesced, and quietly translated it by themselves. Some scholars even learned Chinese by themselves, striving for the first Time to see the original paper.

This time is no exception. Major overseas scientific research institutions have made sufficient preparations. Chinese students are on their seats early. As soon as they get the Chinese version of the electronic journal, they immediately start translating it, enjoying a smooth experience.

After reading the paper, the academic community is completely convinced of oral insulin, and it is waiting for overseas clinical trials to start.

*****

bang bang bang!

Rex closed the office door expressionlessly, then clenched his fists and slammed them on the desk, venting his anger.

As Eli Lilly's new CEO, he is going through the biggest crisis of his career.

The company's stock price plummeted, wiping out tens of billions of dollars in market value in just a few days.

The advent of oral insulin has made the company's key layout, and the diabetes business, which accounts for as much as 50% of revenue, is about to suffer a heavy blow.

Although type 2 diabetes drugs such as GLP-1 receptor agonists are not affected much, the insulin injection business will undoubtedly usher in Waterloo.

Calculated in this way, the loss of insulin alone is as high as 4 billion US dollars per year.

Not to mention, the company has aroused public outrage and is being attacked by public opinion from all over the country, and its reputation value has completely dropped to zero.

It can be said that there is no worse situation than this.

After smashing the desk, Rex vented most of his anger, and began to calm down, thinking about how to deal with it.

Suddenly, there was a knock on the door, and the female secretary pushed the door eagerly and entered.

"Mr. Rex, something is wrong. We have been prosecuted by the Attorney General."

"What?" Ricks stood up abruptly, with veins throbbing on his forehead: "What the hell is going on!"

The secretary handed over a document and said in a hurry: "The Attorney General of California filed a lawsuit against Eli Lilly, Novo Nordisk, and Sanofi, three insulin manufacturers, accusing us of using our market influence to charge excessive fees to diabetic patients. "

"The most important one is that the price of our insulin in Eagle Country is much higher than overseas, and there is a suspicion of price monopoly."

"This accusation has already gained a lot of public support, and even the government is putting pressure on us to implement the insulin price limit as soon as possible."

"Fack!" Rex read the document at a glance, his face turned pale, and he sat down slumped, feeling a sense of powerlessness in his heart.

He never expected that the situation would turn out to be so depraved, presenting a situation where everyone was shouting and beating, adding fuel to the fire.

"You go to hold an executive meeting, and let's discuss this matter together." After thinking for a while, Rex waved his hand and sent the secretary away.

Since it involves litigation, it can only be resolved with the executives.

However, he is also prepared. If the situation is really irreversible, he can only take the old path of resignation.

Half an hour later, all executives gathered in the conference room.

Looking at the indictment, everyone showed a shit-eating expression.

Rex tapped the table and said: "I believe everyone should be very clear about the current situation the company is facing. If you have any good suggestions, you can speak freely."

The director of research and development looked aggrieved: "This group of ungrateful patients, really damn, don't even think about it, if we didn't invest all the money we earned in research and development, and constantly launched new products, where would they get the third generation and the first one?" Four generations of insulin are available."

The others also nodded with sympathy.

Rex said with a blank expression: "There is no need to say anything about complaining, no one wants to hear it. The patient only sees the price of insulin and nothing else."

The sales director hesitated and said: "Currently the most expensive insulin in the world is Eagle Country. Compared with overseas countries, there is indeed a big gap. Otherwise, we can lower the price a little bit and make a gesture, which will surely appease the patients."

"Anyway, we are increasing the price every year. This year it will be lowered a little, and it will be raised again in a few years. The loss is not too big. At least we can deal with the current situation."

Someone immediately agreed: "That's right, patients are easy to fool. As long as we see that we have really lowered the price, the public opinion will naturally calm down. At that time, we will find an excuse to raise it back, and no one can find fault."

Rex asked a little speechlessly: "The price has been reduced and you want to raise it back? Do you think it's the same as before? Forgot to take insulin orally?"

"Do you know how much insulin is sold in Huaxia and Europa? The price difference is ten times!"

He said unceremoniously: "I'll tell you the truth, even if oral insulin is on the market, it will be sold at this price. At a similar price, why should patients choose us instead of oral insulin that is more convenient and has a better experience?" ?”

The executives fell silent for a moment.

These words were like pouring a basin of cold water on the head. Although it made everyone feel cold, it also made people return to reality.

The price of insulin in Yingguo is so high that it has almost reached a ceiling. No matter how high Sanqing’s oral insulin is priced, it cannot be exceeded by much.

This has created a very embarrassing situation. If the price is not reduced, it will definitely be beaten by oral insulin and completely lose this market.

If the price is lowered, relying on the cost advantage, it may be able to form a price difference with oral insulin and retain a certain market.

After all, diabetics take medicine for a long time, and the burden is relatively heavy. Some patients with poor economic conditions are definitely willing to sacrifice experience and choose cheap insulin injections.

The executives looked at me and I looked at you. After a while, they all agreed.

"To be right, I didn't think carefully. To appease the public, the only way to reduce the price is to deal with the competition of oral insulin, or to reduce the price."

"Fortunately, in addition to insulin drugs, we also have ace hypoglycemic drugs such as dulaglutide, and the revenue is still growing every year, which is enough to maintain our competitiveness in the diabetes drug market."

"Yes, GLP-1 receptor agonist drugs have an annual revenue of more than 10 billion U.S. dollars, while insulin only has a revenue of more than 3 billion U.S. dollars. Even if the price is lowered and the low-end route is taken, it will not have a big impact on the company's business. "

"There are relatively few patients with type I diabetes. I suggest that the company should focus on hypoglycemic drugs suitable for type II diabetes in the future."

"In addition to the diabetes business, the company also performed very well in the fields of immunity and nerves. The growth is obvious to all. There is no need to slam insulin, the crooked neck tree, and we can vigorously develop other disease areas."

Rex coughed lightly, and said in a deep voice, "Very well, it seems that we have reached a consensus to use price reductions to find a chance."

"Then, the next question is, how much?"

"This..." Everyone fell silent again.

Yes, it is agreed to reduce the price, so how much will it be reduced?

Rex glanced around and continued, "My suggestion is to reduce the price by 70%, so as to express our sincerity."

The sales director was the first one who couldn't help it anymore, stood up and protested: "This is too much, those dealers will definitely peel off my skin and eat it raw."

Rex's expression did not fluctuate, and he said in a flat tone: "My dear sales director, please allow me to remind you that even if the price is reduced by 70%, our insulin drugs are still more expensive than overseas prices, but not so expensive. It's just obvious."

"Also, besides Sanqing's oral insulin, our competitors include Sanofi, Novo Nordisk, and even Huaxia's Ganli, especially the latter, whose injectable insulin is sold quite cheaply. Huaxia has taken away many of our markets."

"After the price of insulin has been greatly reduced, there are still profits, but it is not as huge as before."

"I believe you will not be willing to give up this market to generic drug manufacturers."

The sales director was at a loss for words, and sat back angrily.

"Okay, it's settled." Seeing that no one objected, Rex immediately made a final decision.

"I will issue an announcement announcing a 70% price cut, which should appease the public, deal with the lawsuit, and boost the stock price at the same time."

"Of course, such a large price cut will definitely not be implemented immediately, but will be delayed until the end of the year, that is, before the launch of Sanqing's oral liquid insulin. The middle period should be enough to recover all the adverse effects and consolidate the established market. gone."

"Guys, let's face this reality. Since Sanqing has developed oral insulin, we will basically have nothing to do with insulin in the future. Let's focus on hypoglycemic drugs."

"Or go a step further and invest R\u0026D in pancreatic stem cell therapy to seize new tracks."

Ricks quickly reported the results of the meeting to the board of directors, which was approved.

Eli Lilly and Company has reached a consensus that due to the soaring annual sales of GLP-1 receptor agonist drugs, it has become the ace drug with a revenue of over 10 billion. Therefore, it is necessary to fully develop this field and gradually abandon insulin products with greatly reduced profit margins. Wire.

GLP-1 receptor agonist is a new type of hypoglycemic drug, which mainly acts on islet β cells, can inhibit the apoptosis of islet β cells, promote the proliferation and regeneration of β cells, thereby promoting the synthesis and secretion of insulin, and achieve the purpose of controlling blood sugar .

This drug is mainly suitable for patients with type II diabetes, because they only have damaged pancreatic beta cells and insufficient insulin secretion, and they are not unable to secrete insulin like patients with type I diabetes.

95% of the world's diabetics are type II, so GLP-1 receptor agonists have a broader market space, and it is no wonder that Lilly will make such a choice.

The next day, Eli Lilly officially announced the heavy news.

"After a series of recent events, Eli Lilly has realized that the price of insulin should not be so expensive, but should be affordable for all people who need it."

"Starting in the fourth quarter of this year, the price of our two best-selling insulin products will be reduced by 70%, and the listing price of other non-branded insulin generics will also be reduced to $25 per vial, which will be the cheapest insulin to take at mealtimes .”

"At the same time, we will also launch a new type of insulin, which is a generic version of Sanofi's insulin, and the price will be set at $90, which is 80% lower than the original price."

"Finally, we also plan to be the first pharmaceutical company to implement an insulin price limit order, limiting out-of-pocket expenses for patients with commercial insurance to $35 per month. As for those without insurance, you can log on to our official website and download Lilly Insulin Value Plan Savings Card, which also gets Lilly insulin for $35 a month."

"The significant price reductions announced today should have a real benefit to Eagle Country's diabetics and have a positive positive impact on society."

"Insulin price cuts should be the new standard in Eagle Country, and we believe other companies and stakeholders should agree on this as well."

After the news came out, it was no less than a major earthquake, and the whole world was stunned.

The financial sector was the first to react. After the stock market opened, Eli Lilly's stock price fluctuated instantly, rising by 2%.

Although it has not rebounded back to the original price, it has begun to rise slowly, and it is estimated that it will recover soon in the near future.

Netizens couldn't believe it at first, because there have been so many reversals recently, they thought the hackers had come back again.

It wasn't until they saw Rex's interview on the news that the rhetoric was exactly the same as the announcement on the Internet that everyone believed it completely.

The Eagle Country Diabetes Association immediately issued a statement, praising Eli Lilly for the price reduction and expressing great anticipation of price reduction announcements from other insulin manufacturers.

As for the compliments from all walks of life, Lilly's reputation has been completely reversed. It has transformed from a greedy vampire into a pioneer of price cuts that is sympathetic to the people.

Netizens stopped scolding Lilly, but cheered and forwarded it happily, and urged other manufacturers to follow up quickly.

"I was wrong. It turns out that vampires really repent."

"Lilly actually lowered the price, grandma, come out and see God!"

"God bless, I can finally afford insulin and I don't have to go all the way to buy smuggled goods."

"I will only buy insulin from Lilly in the future, as for other manufacturers, hurry up and die."

"I have decided that even if I buy imitation insulin in the future, I will only look for Lilly."

Amid the global frenzy, the only losers are the other insulin makers.

Especially Sanofi and Novo Nordisk, they were just gnashing their teeth with anger, wishing they could swallow Lilly alive.

It's just that the public opinion is surging, and they can't expressly oppose the price cut. They can't tell their hardships, so they can only secretly wipe their tears in the toilet.

Lilly's move was preemptive, turning passive into active. Not only did he escape smoothly, but he also put his friends and businessmen on the stake, making him a new target of attacks from netizens across the country.

It even imitated the insulin drugs of its friends in a very rogue manner and sold them at a low price of breaking bones, making it clear that it wanted to grab the market of these two companies.

This wave of capitalism's backstabbing, anyone who saw it had to give a thumbs up and shouted: "Well done!"

Just when Eli Lilly launched a big price cut on insulin, it became red-eyed.

Sanqing's oral insulin has also officially entered Eagle Country, and the third phase of clinical trials has begun.